trending Market Intelligence /marketintelligence/en/news-insights/trending/t02bl8pbpzltvvntq2losw2 content esgSubNav
In This List

ProMetic drug gets US rare pediatric disease designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ProMetic drug gets US rare pediatric disease designation

ProMetic Life Sciences Inc.'s treatment for a form of bowel disease secured the U.S. Food and Drug Administration's rare pediatric disease designation.

ProMetic's inter-alpha-inhibitor-proteins secured the designations for the treatment of necrotizing enterocolitis — a disease where a portion of the bowel dies.

Necrotizing enterocolitis is the most common acquired gastrointestinal disease affecting premature infants. It is characterized by damage to the intestinal wall, leading to perforation of the intestine and spilled stool into the infant's abdomen.

The Canadian biopharmaceutical company secured an orphan drug designation for the treatment earlier in February.

The rare pediatric disease designation is granted to drugs that have the potential to treat orphan diseases affecting fewer than 200,000 patients in the U.S. and with more than 50% of those affected age 18 years or younger.